Attention! Information is for reference only!
Before taking the course, consult a doctor!
WEB SITE ONLY DIRECTORY. NOT PHARMACY! We do not sell medicines! None!

Description of the medicine: Abciximab (Abciximab)


Synonym: ReoPro, ReoPro.

Antiaggregant new generation (created in the early 1990's.). Is a "chimeric" monoclonal antibody. It was obtained by biotechnological method by combining FAB-fractions of mouse antibodies with human immunoglobulin. It has a specific ability to irreversibly bind to platelet IIb / IIIa receptors (causing a change in the conformation of the arginine-glycine-asparaginate receptor binding site), thereby preventing the fixation of fibrinogen, von Willebrand factor and other adhesive molecules (on these receptors) and resulting in a powerful antiplatelet (antithrombotic ) Action.

Unlike the synthetic competitive inhibitors of platelet-derived IIb / IIIa (tirofiban, lamifiban and eptifibatide), abciximab has a high and long affinity for the above receptors, as well as a very short half-life in the blood. In this regard, when introduced into the flow of blood has an immediate effect, but to maintain the effect requires continuous infusion.

Apply (in combination with acetylsalicylic acid and intravenous infusion of heparin) to prevent thrombosis after angioplasty operations (on the coronary arteries, etc.), with acute myocardial infarction, postinfarction and unstable angina.

Intravenous bolus for coronary angioplasty is administered 10 to 60 minutes prior to surgery at 0.25 mg / kg for 1 minute, then infusion at a rate of 0.125 μg / kg per minute (up to 10 μg per 1 minute) for 12 hours. For unstable Angina, the introduction of the drug begins 24 hours before the operation of percutaneous myocardial revascularization.

Possible side effects: bleeding, arterial hypotension, bradycardia, thrombocytopenia, rarely - allergic reactions.

The drug is contraindicated for internal bleeding, hemorrhagic diathesis, aneurysm, severe arterial hypertension, thrombocytopenia, severe kidney or liver damage, pregnancy and breast-feeding.

Before and after 12 and 24 hours after the start of treatment it is necessary to determine hematocrit and hemoglobin and after 2-4 and 24 hours the platelet count in the blood.

The effect of the drug is enhanced by the influence of anticoagulants, factory antidotes and other antiplatelet agents. Nevertheless, with appropriate observation simultaneously with abciximab, acetylsalicylic acid (aspirin) and heparin in small doses are used.

Use abciximab only in a hospital based on strict indications.

Product: 0.2% solution for injection in bottles of 5 and 20 ml.